Additional studies are needed to: i) determine if chemotherapy exposure exacerbates tau pathology and neurodegeneration in tauopathy and AD model systems, ii) mechanistically unravel how chemotherapy-induced tau pathology contributes to CRCI and neurodegeneration, iii) compare the protein structure and posttranslational modifications of chemotherapy-induced tau species with that of AD, and iv) confirm whether chemotherapy patients have increased pathologic tau, which can then be targeted by tau immunotherapies. Here, MAPT is linked to tauopathy.